Physician profile
Sameer Gupta
NPI 1013171420
$380,878.56
in general payments reported to CMS, 2019-2025
85 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $26K · 2021: $58K · 2022: $75K · 2023: $99K · 2024: $39K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $14K · Food and Beverage: $13K · Consulting Fee: $4,795 · Education: $25.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,041.25 |
| Travel and Lodging | $14,229.60 |
| Food and Beverage | $13,005.71 |
| Consulting Fee | $4,795.00 |
| Education | $25.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $262,704.61 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $83,141.14 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $7,015.12 | 2019-2025 | Phesgo, Venclexta, Kadcyla |
| Seagen INC. | $4,262.53 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $3,095.64 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $2,176.05 | 2019-2025 | Padcev, Xtandi, Xospata |
| Astrazeneca Uk Limited | $2,055.00 | 2023 | |
| Eisai INC. | $1,967.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,250.66 | 2019-2025 | Eliquis, Opdivo, Opdualag |
| Pfizer INC. | $1,045.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $980.61 | 2019-2025 | Piqray, Kisqali |
| Lilly USA, LLC | $720.12 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $704.31 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $631.49 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Incyte Corporation | $631.05 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.